Efficacy and safety of zanubrutinib combined with chimeric antigen receptor T-cell therapy targeting CD19 in refractory or relapsed diffuse large B cell lymphoma: A retrospective analysis
Zanubrutinib combined with CAR T-cell therapy offers an effective treatment option for patients with R/R DLBCL, enhancing response rates and survival. Detailed analysis of CAR T-cell expansion provides insight into the dynamics of cellular responses, underscoring the potential for tailored therapeutic approaches based on biological markers.
Authors
- Miao Zheng (ORCID: https://orcid.org/0000-0003-3962-7209)
- Yun Li (ORCID: https://orcid.org/0000-0002-5849-5910)
- Fankai Meng (ORCID: https://orcid.org/0000-0002-6838-3955)
- Xiaoying Zhang (ORCID: https://orcid.org/0000-0002-6637-7025)
- Jinhuan Xu (ORCID: https://orcid.org/0000-0002-4344-6913)
- Yicheng Zhang
Institutions
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Cancer Treatment and Research Communications
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.ctarc.2025.100902
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.09